Table 4 Summary of various indicators implying the potential significance of CARM1 in different tumors
Tumor type | CARM1 RNA expression | CARM1 protein expression | High vs Low CARM1 expression group | Predominant genomic alterations | Survival (altered vs unaltered group) | Correlation with CARM1 mRNA expression | Prognostic value assessment | Evidence from in vitro/in vivo cancer model studies | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OS | DFS | TMB | MSI | Tumor neoantigen | Researches on CARM1 in this cancer | Effect of CARM1 on this cancer | ||||||
ACC | NS | Related to the pathological stages | ** | *** | Amplification (3.3%) | NA | PC ** | NS | NS | Unfavorable | NA | NA |
BLCA | Up | Correlated with subtypes | ** | ** | Amplification (2.19%) | DFS* | NS | NS | NS | Unfavorable | NA | NA |
BRCA | Up | Up | **# | NA | Amplification (1.29%) | NS | PC ** | NS | PC ** | Unfavorable, potentially associated with HER2 expression | Pro-tumorgenic | |
CESE | NS | NA | NA | NA | Amplification (1.35%) | PFS*/DFS*** | NS | NS | NS | Unfavorable | NA | NA |
CHOL | Up | NA | NA | NA | NA | NS | NS | NS | NS | Not prognostic | NA | NA |
COAD | Up | Up | NA | NA | Mutation (0.84%) | PFS*/DFS* | NS | NS | NS | Unfavorable | NA | NA |
DLBC | Up | NA | NA | NA | Deep deletion (4.17%) | NA | NS | NC ** | NA | Not prognostic | [19] | Pro-tumorgenic |
ESCA | Up | Related to the pathological stages | NA | NA | Deep deletion (1.1%) | NA | NS | NS | NA | Not enough evidence | NA | NA |
GBM | NS | NA | * | NA | Amplification (0.84%) | NS | NS | NS | NS | Not enough evidence | [20] | Pro-proliferative |
HNSC | Up | NA | * | NA | Mutation/Amplification (0.96%) | OS** | PC ** | NC ** | NA | Unfavorable, related to TME | NA | NA |
KICH | Down | Down | NA | NA | NA | NA | NS | NS | NA | Not enough evidence | NA | NA |
KIRC | Down | Up | *** | NA | Mutation (0.35%) | NA | NS | NS | NS | Unfavorable, related to TME | NA | NA |
KIRP | NS | NA | *** | NA | NA | NA | NC * | NS | NS | Unfavorable, related to TME | NA | NA |
LAML | NS | NA | NA | NA | Amplification (0.5%) | NA | NS | NS | NA | Not prognostic | [21] | Pro-tumorgenic |
LGG | NS | NA | *** | ** | Amplification (1.95%) | NA | PC *** | NS | NS | Unfavorable | NA | NA |
LIHC | Up | NA | NS# | NA | Deep deletion (0.27%) | NA | NC * | NS | NS | Favorable in some subgroups | Pro-proliferative; Antiproliferative | |
LUAD | Up | Up | *** | NA | Mutation (0.88%) | NS | PC *** | PC * | NS | Unfavorable | [23] | Pro-proliferative |
LUSC | Up | Up | *** | NA | Amplification (1.23%) | NS | NS | PC *** | NS | Unfavorable, related to TME | NA | NA |
MESO | NA | NA | *** | * | Amplification (2.3%) | NA | NS | NS | NA | Unfavorable | NA | NA |
OV | NS | NA | NS# | NA | Amplification (7.88%) | NA | NS | NS | NS | Vary from subgroups | NA | NA |
PAAD | NS | NA | * | NA | Mutation (1.09%) | NA | PC * | NS | NA | Not enough evidence | [5] | Antiproliferative |
PCPG | Up | NA | NA | NA | NA | NA | NS | NS | NA | Not prognostic | NA | NA |
PRAD | Up | NA | NA | NA | Structural variant (0.4%) | DFS* | NS | NS | NS | Not enough evidence | [24] | Pro-tumorigenic |
READ | Up | NA | NA | NA | NA | NA | NS | NC *** | NS | Not prognostic | NA | NA |
SARC | NS | NA | NA | NA | Amplification (5.1%) | NA | PC ** | PC ** | NA | Not prognostic | [25] | Pro-proliferative |
SKCM | NS | NA | ** | NA | Mutation (2.03%) | NS | PC * | NC ** | NS | Not enough evidence | NA | NA |
STAD | Up | NA | NA | NA | Mutation (1.82%) | OS* | PC *** | PC * | PC * | Not enough evidence | NA | NA |
TGCT | NS | NA | * | NA | NA | NA | NS | NS | NA | Not enough evidence | NA | NA |
THCA | Up | NA | NS | NA | NA | NA | NC *** | NS | NS | Not prognostic, related to TME | NA | NA |
THYM | Up | NA | NA | NA | NA | NA | NS | NS | NA | Related to TME | NA | NA |
UCEC | Up | NS | NA | NA | Amplification (4.35%) | NA | NS | NS | NS | Not prognostic | NA | NA |
UCS | NS | Related to the pathological stages | NA | * | Amplification (7.02%) | NS | NS | NS | NA | Not enough evidence | NA | NA |
UVM | NA | NA | NA | * | Amplification (1.25%) | NA | NS | PC * | NA | Not enough evidence | NA | NA |